ACT + Ketamine for Depression
(K-ACT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Ketamine is often used to treat depression where standard treatments have failed. Yet, even with ketamine, depression can persist and make it difficult to keep up with life. This study examines whether it is practical, safe and helpful to use a talk therapy (Acceptance and Commitment Therapy, ACT) in patients with difficult-to-treat depression receiving ketamine through the Ketamine Intervention Program at UBC Hospital. Researchers expect that combining ACT plus Ketamine ("K-ACT") will be feasible, safe, and will help patients functioning better in their daily lives, feeling that they are recovering, and having fewer symptoms of depression.
Are You a Good Fit for This Trial?
This trial is for adults with depression that hasn't improved after standard treatments, who are receiving ketamine at UBC Hospital. Participants should be able to take part in talk therapy sessions.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- K-ACT Intervention
Trial Overview
The study tests whether combining Acceptance and Commitment Therapy (a type of talk therapy) with ketamine treatment helps people with hard-to-treat depression feel better and function more effectively.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of British Columbia
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.